2,5-DKG permeases

Details 2,5-DKG permeases 2,5-DKG permeases

2001-08-03

2004-04-13

Patterson, Jr., Charles L. (Department: 1652)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Preparing compound containing saccharide radical

C435S320100, C435S252000, C435S252330, C536S027200

Reexamination Certificate

active

06720168

ABSTRACT:

BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
The present invention relates generally to microbial transporter proteins and, more specifically, to novel 2,5-diketo-D-gluconic acid (2,5-DKG) permeases.
BACKGROUND INFORMATION
Adequate intake of ascorbic acid, or vitamin C, is recognized as an important factor in maintaining health. To ensure adequate intake of ascorbic acid, the chemical is now added to many foods, drinks and cosmetic products, and is also sold as a direct vitamin supplement. To meet the commercial demand for ascorbic acid, there is a need to develop more efficient processes for its production.
Although there are a number of alternative methods of producing ascorbic acid, one of the least expensive and most ecologically sound methods is biofermentation. Bacterial strains have now been engineered to express all of the enzymes required for the stepwise conversion of an inexpensive sugar source, such as D-glucose, to a stable precursor of ascorbic acid, 2-keto-L-gulonic acid (2-KLG) (see U.S. Pat. No. 5,032,514 and references therein). 2-KLG can be readily converted to ascorbic acid by chemical or enzymatic procedures.
FIG. 2
shows schematically the enzymatic reactions that take place in the bioconversion of D-glucose to 2-KLG. As shown in
FIG. 2
, the enzymatic reactions that lead from D-glucose, to D-gluconic acid, to 2-keto-D-gluconic acid (2-KDG), to 2,5-diketo-D-gluconic acid (2,5-DKG), take place at the surface of the bacterial cell. 2,5-DKG must then enter the cell in order for its enzymatic conversion to 2-KLG.
Much effort has been expended in increasing the efficiency of the enzymatic reactions involved in 2-KLG production. For example, U.S. Pat. No. 5,032,514 describes methods for increasing 2-KLG production by reducing metabolic diversion of 2,5-DKG to products other than 2-KLG.
Increasing uptake of 2,5-DKG by a bacterial strain suitable for biofermentation could be advantageous in increasing 2-KLG production. Expressing additional copies of an endogenous 2,5-DKG permease, or expressing an exogenous 2,5-DKG permease with superior properties, could increase uptake of 2,5-DKG. However, to date, no 2,5-DKG permease has been identified or characterized that could be used in this manner.
Therefore, there exists a need to identify and characterize nucleic acid molecules encoding 2,5-DKG permeases, so that permeases with advantageous properties can be used in the commercial production of ascorbic acid and in other important applications. The present invention satisfies this need and provides related advantages as well.
SUMMARY OF THE INVENTION
The invention provides an isolated nucleic acid molecule encoding a polypeptide which has 2,5-DKG permease activity. In one embodiment, the isolated nucleic acid molecule contains a nucleotide sequence having at least 40% identity to a nucleotide sequence selected from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9 and 11. In another embodiment, the isolated nucleic acid molecule contains a nucleotide sequence which encodes a polypeptide having at least 40% identity to an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10 and 12.
Also provided are vectors and cells containing isolated nucleic acid molecules encoding polypeptides having 2,5-KDG permease activity. In one embodiment, the cells are bacterial cells selected from the genera Pantoea and Klebsiella.
The invention also provides methods of identifying and isolating nucleic acid molecules encoding polypeptides which have 2,5-DKG permease activity. Also provided are methods of enhancing 2-KLG production, by expressing the nucleic acid molecules of the invention in suitable bacterial cells.
Further provided are isolated polypeptides having 2,5-DKG permease activity, and immunogenic peptides therefrom. The invention also provides antibodies specific for such polypeptides and peptides.


REFERENCES:
patent: 4757012 (1988-07-01), Estell et al.
patent: 5032514 (1991-07-01), Anderson et al.
patent: 5047340 (1991-09-01), Dickson et al.
patent: 5783431 (1998-07-01), Peterson et al.
patent: 5912161 (1999-06-01), Lazarus et al.
patent: 5958672 (1999-09-01), Short
patent: 5989891 (1999-11-01), Liaw et al.
patent: 6368793 (2002-04-01), Hoch et al.
patent: 195 23 279 (1997-01-01), None
patent: 0 839 909 (1998-05-01), None
patent: 2 736 652 (1997-01-01), None
patent: WO 95/10613 (1995-04-01), None
patent: WO 97/25432 (1997-07-01), None
patent: WO 98/18936 (1998-05-01), None
patent: WO 02/12528 (2002-02-01), None
Muzny, D., et al. (1998) Acc. No. AC002890.*
Mason, K.A, et al. (1998) Acc. No. AF064803.*
Bausch et al., Sequence analysis of the Gntil (subsidiary) system for gluconate metabolism reveals a novel pathway for L -idonic acid catabolism inEscherichia coli, J. of Bacteriology, V. 180(14), Jul. 1998, pp. 3704-3710.
Boudrant, J. “Microbial processes for ascorbic acid biosynthesis: a review,”Enzyme and Microbial Technology, V. 12,(5), May 1, 1990, pp. 322-329.
Chotani, et al., The commerical production of chemicals using pathway engineering,Biochimica et Biophysica acta, V. 1543 (2), Dec. 2000, pp. 434-455.
*Hamilton et al., “New Method for Generating Deletions and Gene Replacements,”J. Bacteriol., vol. 171, No. 9, pp. 4617-4622, 1989.
Hamood et al.,Pseudomonas aeruginosaPtxR (ptxR) and PtxS) genes, complete cds and ketogluconate utilization operon gene, complete sequence, Database accession No. AF012100 XP002204795.
Klemm, et al., “The gntP Gene ofEscherichia coliinvolved in Gluconate Uptake,”J. of Bacteriology, Jan. 1996, p. 61-67, V178 (1).
Kramer, R., <<Genetic and physiological approaches for the production of amino acids>>, J. of Biotechnology, Elsevier Science Publishers, Amsterdam, NL, V.45(1), Feb. 12, 1996,pp. 1-21.
Pao et al., <<Major facilitator superfamily,>> Microbiology and Molecular Biology Reviews, V.62(1), Mar., 1998, pp. 1-34.
*Lerner et al., “Low copy number plasmids for regulating low-level expression of cloned genes inEscherichia coliwith blue/white insert screening capability,”Nucleic Acids Res., vol. 18, No. 15, pp. 4631, 1990.
Peekhaus, et al., Characterization of a novel transporter family that includes multipleEscherichia coligluconate transporters and their homologues,Fems Microbiology Letters, V. 147(2), 1997, pp. 233-238.
Saito, et al. “Direct fermentation of 2-Keto-L-gulonic acid in recombinant Gluconobacter oxydans,”Biotechnology and Bioengineering, V. 58(2-3), Apr. 20, 1988, pp. 309-315.
*Steicher et al., “Transduction of the Nitrogen-fixation genes inKlebsiella pneumoniae,” Proc. Natl. Acad. Sci., vol. 68, pp. 1174-1177, 1971.
*Swanson et al., “Characterization of the 2-ketogluconate utilization operon inPseudomonas aeruginosaPA01,”molecular microbiology, 37(3):561-575 (2000).
Yew, et al., <<Utilization of L-ascorbate byEscheriuchia coliK-12: Assignments of functions to products of the yjf-sga and yia-sgb operons,>>J. of Bacteriology, V. 184 (1), Jan. 2002, pp. 302-306.
Eroshkin et al., “Algorithm and cmputer program Pro_Anal for analysis of relationship between structure and activity in a family of proteins or peptides,”Comput. Appl. Biosci., vol. 9, pp. 491-497, 1993.
Higgens, D., “Clustal V: Multiple Alignment of DNA and Protein Sequences,”Methods Mol. Biol., vol. 25, pp. 307-318, 1994.
Huse et al., “Geneation of a Large combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda,”Science, vol. 246, pp. 1275-1281, 1989.
Imaten et al., “Prediction of epitopes and production of monoclonal antibodies against gastric H,K-ATPase,”Protein Eng., vol. 11, No. 10, pp. 949-955, 1998.
Savoie et al., “Use of BONSAI decision trees for the identification of potential MHC Class 1 peptide epitope motifs,”Pac Symp. Biocomput., 1999:184-189, 1999.
Ward et al., Binding activities of a reperire of single immunoglobulin variable domains secreted fromEscherichia coli, Nature, vol. 341, pp. 544-546, 1989.

Affiliated with

Also associated with

Rating

2,5-DKG permeases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 2,5-DKG permeases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2,5-DKG permeases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3248376